tiprankstipranks
CervoMed (CRVO)
NASDAQ:CRVO
US Market
CRVO
CervoMed
RESEARCH TOOLSreports

CervoMed (CRVO) Stock News & Sentiment

1,244 Followers
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
Premium
Company Announcements
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
5d ago
8K
CRVO
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
Premium
Company Announcements
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
20d ago
8K
CRVO
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
Premium
Company Announcements
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
24d ago
8K
CRVO
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
Premium
Company Announcements
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
26d ago
8K
CRVO
CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
Premium
Ratings
CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
27d ago
CRVO
CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target
Premium
Ratings
CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target
27d ago
CRVO
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs
Premium
Company Announcements
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs
29d ago
CRVO
More CRVO News >

CRVO News on the Web

CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
TipRanks News
Neutral
CervoMed (CRVO) Gets a Buy from JonesTrading
TipRanks News
Neutral
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
TipRanks News
Neutral
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
TipRanks News
Neutral
CervoMed’s neflamapimod shows efficacy in dementia with DLB
TipRanks News
Bullish
CervoMed Narrows Cash Runway As It Prepares For Multiple 2026 Clinical Milestones
rttnews
Bullish
CervoMed price target lowered to $11 from $19 at Roth Capital
TipRanks News
Bullish
Chardan Capital Sticks to Their Buy Rating for CervoMed (CRVO)
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
CRVO
Sector Average
Media Buzz
This Week2 articles
Weekly Average3.25 articles
News Sentiment
This Week50%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CRVO’s Media Buzz Sentiment?
2 articles about CRVO were published this week. In an average week, 3.25 articles are published.
    What is CRVO’s weekly average amount of articles?
    In an average week, 3.25 articles about CRVO are published.
      What is CRVO’s News Sentiment?
      50% of articles about CRVO were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week